Grants4Apps Accelerator and new Dealmaker now open for submissions

The Grants4Apps Accelerator Berlin is back and this time with an additional track for the mature startups out there: The Dealmaker. Up to five startups will be selected for the 100-day Accelerator program in Berlin. The new Dealmaker is all about quality facetime between you and Grants4Apps experts for one full day.

Grants4Apps Accelerator Berlin 2017

Startups receive € 50,000 each as well as office space in the Bayer Pharmaceuticals Headquarters. Additionally, C-level mentors will support in refining business models, validating technologies and more.

The Grants4Apps team is looking for startups with innovative healthcare solutions. The team is open for any healthcare topics and will give special attention to Bayer-relevant focus areas. This year Grants4Apps is focusing on digital health solutions in the areas of Nephrology (e.g., Chronic Kidney Disease), Women's Health (e.g., Endometriosis), Pulmonology (e.g., Pulmonary Hypertension), Cardiology (e.g., Atrial Fibrillation), Hematology, Oncology, Radiology, Infectious Diseases and Ophthalmology (e.g., Diabetic Retinopathy).

Grants4Apps is also calling for collaboration projects using software or hardware to be applied in clinical trials and medical IT using state-of-the art-technologies such as artificial intelligence, machine learning, deep learning, sophisticated algorithms, bioinformatics, genomics analysis, novel approaches for Electronic Health Records (EHR) etc. - in short: highly innovative technologies with a taste for excellent simplicity and unbeatable user experience focus.

Submission deadline: 31 May 2017

For further information, please visit:
https://www.grants4apps.com/berlin/program/accelerator-berlin-2017/

Dealmaker Berlin 2017

Don't need acceleration? Want to gain Bayer as a potential customer? Then this is for you! Mature startups can apply to solve specific 'Bayer challenges'. The top startup matches will have the opportunity to come to Berlin in September (travelling costs will be covered by Bayer) and to sign a potential project deal, please find the challenge you can solve.

If there is a match, you will be inviteed to Berlin to pitch your solution, discuss collaboration options and close a deal. Find out, if there is a mutual interest to start a bigger journey.

Applicants are asked to address one or multiple challenges. However, the Dealmaker is also open for other solutions that help healthcare providers or patients, as well as products dedicated to preventing or diagnosing diseases or improving pharmaceutical processes.

Submission deadline: 30 June 2017

For further information, please visit:
https://www.grants4apps.com/berlin/program/dealmaker-berlin-2017/

About Grants4Apps®
We connect health startups with industry experts and help the best talents to thrive within the digital healthcare universe. We are looking for startups beyond the ideation phase developing health technology or IT solutions that can connect and empower patients or healthcare stakeholders.

There are no boundaries to creativity!

Most Popular Now

Johnson & Johnson announces advance purchase a…

Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vacci...

Pfizer and BioNTech confirm high efficacy and no s…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pi...

Pfizer-BioNTech announce positive topline results …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SAR...

GSK to support manufacture of Novavax' COVID-19 va…

GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax' COVID-19 va...

Valneva reports positive Phase 1/2 data for its in…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Clinical trial completion rates decline during COV…

Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected c...

BioNTech provides update on vaccine production sta…

BioNTech SE today announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. As part o...

COVID-19 convalescent plasma with greater antibody…

Convalescent plasma, the use of survivors' antibodies transfused into sick COVID-19 patients is safe and significantly improves clinical outcomes when using high levels o...

Pfizer and BioNTech request regulatory agencies ex…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today requested amendments to the U.S. Emergency Use Authorization (EUA) of the Pfizer-BioNTech vaccine (BNT162b2) ...

Study identifies possible COVID-19 drugs - includi…

A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that ...

COVID-19 causes 'unexpected' cellular response in …

New insights into the immune response to SARS-CoV-2 infections could bring better treatments for COVID-19 cases. An international team of researchers unexpectedly foun...

Undetected coronavirus variant was in at least 15 …

A highly contagious SARS-CoV-2 variant was unknowingly spreading for months in the United States by October 2020, according to a new study from researchers with The Unive...